

## 2019-nCoV Spike protein **RBD (S477G)** Catalog No: C19SD-G231BH

Mutation at S477 in the RBD region of the spike protein has been found to strengthen the binding of the SARS-CoV-2 spike with the ACE2 receptor. As the new variants displace the first-wave virus, it is and their possible tendency to escape antibody neutralization.

- SignalChem's recombinant 2019-nCoV Spike protein S1 subunit, RBD (S477G) was expressed in CHO cells using a C-terminal his tag.
- The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein that recognizes the host ACE2 receptor is a major determinant of viral entry and neutralization, and is the most divergent

## **Product Features**



90% Purity



stratech.co.uk/signalchem info@stratech.co.uk

Stratech

**Fully Functional** Protein



Expressed in CHO cells

QA/QC Tested

Target Customers



**Applications** 

**Recombinant Antibody** production



Western Blot

Government research organizations



Scientists testing Covid19 inhibitors



Covid19 protein arrays



**Diagnostic kits** R&D



**Biopharma companies** developing vaccine



Scientists developing targeted anti-Spike protein antiviral therapies